...
首页> 外文期刊>Kidney and blood pressure research >Serum Cystatin C Predicts AKI and the Prognosis of Patients in Coronary Care Unit: a Prospective, Observational Study
【24h】

Serum Cystatin C Predicts AKI and the Prognosis of Patients in Coronary Care Unit: a Prospective, Observational Study

机译:血清胱抑素C可预测AKI和冠心病患者的预后:一项前瞻性观察研究

获取原文
           

摘要

Background/Aims: Acute Kidney Injury (AKI) is a serious clinical state associated with high morbidity and mortality, particularly in critical ill patients. We investigated the hypothesis that serum Cystatin C (sCysC) is a good predictor for AKI and may affect the short-term prognosis of coronary care unit (CCU) patients. Methods: In this prospective, observational study, we screened 412 adults admitted to the CCU from January 1, 2014 to June 1, 2015 at Zhongnan Hospital of Wuhan University. Serum samples were obtained at the time of admission, and sCysC was quantified through nephelometry. AKI was defined based on KDIGO-AKI criteria. After the patients’ hospital discharge, the survivors in this study were followed up for up to 2 years. The primary endpoint was the incidence of AKI stratified by severity stage, while the second endpoints included 2-year mortality, rehospitalization and failure in renal recovery rates, as well as the progression of AKI to CKD. Results: According to the KDIGO-AKI criteria, AKI occurred in 130 (31.6%) patients. After multivariate adjustments, the highest quartile of sCysC was associated with a 9-fold increased risk of incident AKI compared with the lowest quartile. For predicting AKI, sCysC [area under the receiver operating characteristic curve (AUC=0.842)] outperformed β2-micro globulin (AUC=0.813) and the clinical model (AUC=0.777), and a cutoff of 1.255 mg/L yielded good sensitivity and specificity. After a median 19.8-month follow-up, 112 (27.2%) patients died within 2 years after admission. The sCysC independently predicted the risk of 2-year mortality [adjusted odds ratio (OR), 4.955; 95% confidence interval (95% CI), 2.853 to 8.603] and rehospitalization (OR, 3.128; 95% CI, 2.011 to 4.867), as well as renal recovery failure (OR, 3.618, 95% CI, 1.753 to 7.463). Conclusions: Serum CysC is a strong predictor of AKI and the short-term prognosis of CCU patients.
机译:背景/目的:急性肾损伤(AKI)是一种严重的临床状态,与高发病率和高死亡率相关,尤其是在重症患者中。我们调查了血清胱抑素C(sCysC)是AKI的良好预测指标,并可能影响冠心病监护单位(CCU)患者的短期预后的假说。方法:在这项前瞻性观察性研究中,我们筛选了2014年1月1日至2015年6月1日在武汉大学中南医院收治的412例成人。入院时获取血清样本,并通过比浊法定量sCysC。 AKI是根据KDIGO-AKI标准定义的。患者出院后,对这项研究中的幸存者进行了长达2年的随访。主要终点是按严重程度分级的AKI发生率,而第二个终点包括2年死亡率,再次住院和肾恢复率衰竭以及AKI向CKD的进展。结果:根据KDIGO-AKI标准,AKI发生在130(31.6%)位患者中。经过多变量调整后,与最低四分位数相比,sCysC的最高四分位数与发生AKI的风险增加了9倍。为了预测AKI,sCysC [受体工作特征曲线下的面积(AUC = 0.842)]胜过β2-微球蛋白(AUC = 0.813)和临床模型(AUC = 0.777),并且临界值为1.255 mg / L产生了良好的敏感性和特异性。在进行了中位数19.8个月的随访后,入院后2年内有112例患者(27.2%)死亡。 sCysC独立预测了2年死亡率的风险[校正比值比(OR)为4.955; 95%置信区间(95%CI),为2.853至8.603]和重新住院治疗(OR,3.128; 95%CI,为2.011至4.867),以及肾脏恢复失败(OR,3.618,95%CI,为1.753至7.463)。结论:血清CysC是AKI和CCU患者短期预后的有力预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号